electroCore (ECOR) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

$37.0M

Revenue (quarter)

$9.4M

Revenue growth (year over year)

+28.03%

Gross profit (trailing twelve months)

$32.2M

Gross margin

87.06%

Net income (trailing twelve months)

−$14.8M

Net income (quarter)

−$3.1M

Net income growth (year over year)

+16.67%

Net margin

−39.96%

Return on equity

—

EPS (trailing twelve months)

−$1.65

Book value per share

−$0.31

P/E (trailing twelve months)

—

Price to book

—

Debt to assets

116.35%

Payout ratio

—

Dividend yield

—

Company profile

electroCore Inc is a bioelectronic technology company whose mission is to improve health and quality of life through non-invasive bioelectronic technologies. Its two commercial products are gammaCore non-invasive vagus nerve stimulation, or nVNS, and Quell Fibromyalgia, or Quell. It also sells Truvaga and TAC-STIM products, which are handheld, personal-use consumer products developed to promote general wellness and human performance. It operates in one segment: Bioelectronic Innovations. Geographically, it operates in the United States, the United Kingdom, Japan, and Other.

• Is electroCore (ECOR) profitable?

  No. electroCore reported a net loss of $14.8M over the trailing twelve months.

• How much revenue does electroCore (ECOR) make?

  electroCore generated $37.0M in revenue over the trailing twelve months, up 28.03% year over year.

• How do I buy stock in electroCore (ECOR)?

  ECOR trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.